

This material is an English translation of the press release announced on Feb 27, 2020 in Japanese, and the Japanese release is given priority about the content and the interpretation.

Feb 27, 2020

**Notification of application for manufacturing and marketing approval of
HP-3150 for “cancer pain” in Japan
(Transdermal, pain treatment NSAID patch)**

Hisamitsu Pharmaceutical Co., Inc. (Head Office: Tosu city, Saga Prefecture, Japan; President and CEO: Kazuhide Nakatomi, hereinafter referred to as “Hisamitsu”) announces that it has been submitted a new drug application in Japan for the transdermal, pain treatment NSAID patch for “cancer pain” (Development code: HP-3150, generic name: diclofenac sodium, hereinafter referred to as “the product”).

The product is a systemic transdermal formulation developed using Hisamitsu’s TDDS (Transdermal Drug Delivery System) technology. Hisamitsu expects it to be a new option for the treatment of cancer pain to realize its long-lasting effect by means of maintaining a stable blood concentration.

Hisamitsu aims to obtain a manufacturing and marketing approval during FY2020.